I work in the forefront of psychedelic science, business and ethics to help address the global mental health challenge. I have almost twenty years researching psychedelics, including a solid academic trajectory in the interface between psychology, neuroscience and psychiatry. During my undergrad, Masters and PhD studies and post-doctoral research, I specialised in psychedelic substances (ayahuasca, LSD, ibogaine, MDMA and psilocybin, among others). I led and participated in groundbreaking research revealing the neural basis of psychedelic's effects in the human brain, helping to elucidate their effects in consciousness and also their promising therapeutic potentials. I have professional experiences with the first, second and third sectors (government, business and non-profits). My current work, as researcher and consultant, focus on steering the psychedelic therapy market towards ethical developments for radical and disruptive innovations in psychiatry, developing safer and better treatments than currently available, focusing on severe cases of drug addiction, depression and trauma, among others.